OptimizeRx OPRX Amortization expense related to capitalized debt issuance costs
Amortization expense related to capitalized debt issuance costs at other companies
Other financials
Where this comes from
Reported directly by OptimizeRx in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.
The official record: OptimizeRx’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about OptimizeRx's amortization expense related to capitalized debt issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is OptimizeRx's amortization expense related to capitalized debt issuance costs?
- OptimizeRx (OPRX) reported amortization expense related to capitalized debt issuance costs of $358K in Q1 2026.
- How has OptimizeRx's amortization expense related to capitalized debt issuance costs changed year-over-year?
- OptimizeRx's amortization expense related to capitalized debt issuance costs increased by 105.7% year-over-year, from $174K to $358K.
- What is the long-term trend for OptimizeRx's amortization expense related to capitalized debt issuance costs?
- Over 2 years (2023 to 2025), OptimizeRx's amortization expense related to capitalized debt issuance costs has grown at a 129.4% compound annual growth rate (CAGR), from $211K to $1.11M.